Core Viewpoint - ADC Therapeutics SA is set to report its financial results for Q2 2024 and provide operational updates during a conference call on August 6, 2024 [1] Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors through its proprietary ADC technology [2] - ADC Therapeutics' CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy, alongside multiple ADCs in clinical and preclinical development [2] Operational Details - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [3] - A live webcast of the upcoming conference call will be available on the ADC Therapeutics website, with an archived version accessible for 30 days post-call [1]

Company Overview - Myricx Bio is a UK biotech company focused on developing a novel class of payloads for antibody-drug conjugates (ADCs) based on inhibitors of N-Myristoyltransferases (NMT) for cancer treatment [7] - The company was founded by Prof. Ed Tate, Dr. Roberto Solari, and Dr. Andrew Bell, and has transitioned from a virtual company to a fully-fledged R&D company with its own laboratories and in-house R&D team [5][6] Funding and Investment - Myricx Bio has successfully closed a £90 million ($114 million) Series A financing round, co-led by Novo Holdings and Abingworth, with participation from British Patient Capital, Cancer Research Horizons, and Eli Lilly [1][2] - The funds will be utilized to expand Myricx's proprietary NMTi ADC payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept [2][3] Scientific Advancements - Myricx has demonstrated that its initial NMTi-ADCs achieve complete and durable tumor regressions at well-tolerated doses in multiple solid cancer models [3] - The NMTi-ADCs show potent bystander activity and deliver high efficacy in patient-derived xenograft (PDX) organoid models across a broad range of antigen expression levels [3] Management and Strategic Growth - The company is establishing laboratory operations in London's biotech hub and expanding its management and R&D teams [1][5] - New board members include Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth, indicating strong support from leading life science investors [1][2] Market Position and Future Outlook - Myricx aims to address serious unmet needs in oncology with its innovative NMTi payload chemistry platform, which has shown excellent preclinical efficacy and safety [2][7] - The company is well-positioned to leverage its NMTi-ADC platform and advance both its pipeline and strategic partnerships, aiming to become a significant player in the ADC space [5][6]

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the f ...

Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality. It comes down to the same theme. Good health is ultimately more important than any amount of money you can generate. Therefore, biotech stocks to buy offer a permanently relevant storyline. That's no ...

LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. Abo ...

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] - ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey [3] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024 [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [1]

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [3] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024 [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [1]

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [3] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, at 1:35 p.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [1]

Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, at 1:35 p.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [1]